Polycomb-independent activity of EZH2 in castration resistant prostate cancer

被引：0
|
作者：
Kexin Xu
Zhenhua Jeremy Wu
Anna C Groner
Housheng Hansen He
Changmeng Cai
Edward C Stack
Massimo Loda
Tao Liu
Colm Morrissey
Robert L Vessella
Philip W Kantoff
Steven P Balk
X Shirley Liu
Myles Brown
机构：
[1] Dana-Farber Cancer Institute,Center for Functional Cancer Epigenetics
[2] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology
[3] Dana-Farber Cancer Institute and Harvard School of Public Health,Department of Biostatistics and Computational Biology
[4] Beth Israel Deaconess Medical Center and Harvard Medical School,Hematology
[5] Dana-Farber Cancer Institute,Oncology Division, Department of Medicine
[6] Harvard Medical School,Center for Molecular Oncologic Pathology
[7] King’s College London,Department of Pathology, Brigham and Women’s Hospital
[8] University of Washington Medical Center,Division of Cancer Studies
[9] Puget Sound VA Health Care System,Department of Urology
来源：
Epigenetics & Chromatin | / 6卷 / Suppl 1期
关键词：
Androgen Receptor; Acute Leukemia; Castration Resistant Prostate Cancer; Histone Methyltransferase; Methyltransferase Activity;
D O I：
10.1186/1756-8935-6-S1-O14
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
    Wu, Changping
    Jin, Xin
    Yang, Jing
    Yang, Yinhui
    He, Yundong
    Ding, Liya
    Pan, Yunqian
    Chen, Shuai
    Jiang, Jingting
    Huang, Haojie
    ONCOTARGET, 2016, 7 (03) : 3430 - 3442
  • [42] The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer
    Saramaki, Outi R.
    Tammela, Teuvo L. J.
    Martikainen, Paula M.
    Vessella, Robert L.
    Visakorpi, Tapio
    GENES CHROMOSOMES & CANCER, 2006, 45 (07): : 639 - 645
  • [43] Repression of Id4 (inhibitor of DNA binding 4) by the polycomb group protein EZH2 in prostate cancer
    Chinaranagari, Swathi
    Sharma, Pankaj
    Chaudhary, Jaideep
    CANCER RESEARCH, 2013, 73
  • [44] Targeting EZH2 catalytic independent functions in breast cancer
    Lim, Keng Gat
    CANCER RESEARCH, 2015, 75
  • [45] Survival of skin cancer stem cells requires the Ezh2 polycomb group protein
    Adhikary, Gautam
    Grun, Daniel
    Balasubramanian, Sivaprakasam
    Kerr, Candace
    Huang, Jennifer M.
    Eckert, Richard L.
    CARCINOGENESIS, 2015, 36 (07) : 800 - 810
  • [46] Repression of E-Cadherin by the Polycomb Group Protein EZH2 in Pancreatic Cancer
    Toll, A. D.
    Dasgupta, A.
    Potoczek, M.
    Kleer, C. G.
    Brody, J. R.
    Witkiewicz, A. K.
    LABORATORY INVESTIGATION, 2010, 90 : 372A - 372A
  • [47] Repression of E-Cadherin by the Polycomb Group Protein EZH2 in Pancreatic Cancer
    Toll, A. D.
    Dasgupta, A.
    Potoczek, M.
    Kleer, C. G.
    Brody, J. R.
    Witkiewicz, A. K.
    MODERN PATHOLOGY, 2010, 23 : 372A - 372A
  • [48] EZH2 promotes proliferation and invasiveness of prostate cancer cells
    Bryant, R. J.
    Cross, N. A.
    Eaton, C. L.
    Hamdy, F. C.
    Cunliffe, V. T.
    PROSTATE, 2007, 67 (05): : 547 - 556
  • [49] A rare variant in EZH2 is associated with prostate cancer risk
    Raspin, Kelsie
    FitzGerald, Liesel M.
    Marthick, James R.
    Field, Matt A.
    Malley, Roslyn C.
    Banks, Annette
    Donovan, Shaun
    Thomson, Russell J.
    Foley, Georgea R.
    Stanford, Janet L.
    Dickinson, Joanne L.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (05) : 1089 - 1099
  • [50] EZH2 overexpression as a biomarker of poor prognosis in prostate cancer
    Gu, Xiaobin
    Gao, Xian-Shu
    Bai, Yun
    Cui, Ming
    Xiong, Wei
    Han, Linjun
    Guo, Wei
    Xie, Mu
    Peng, Chuan
    Su, Mengmeng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 21829 - 21835
12345